For the quarter ending 2025-09-30, LPCN had -$2,142,940 decrease in cash & cash equivalents over the period.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Non-cash loss on change in fair value of warrant liability | - | 0 |
| Net loss | -3,186,832 | -4,070,589 |
| Depreciation expense | 14,123 | 31,678 |
| Stock-based compensation expense | 53,256 | 136,207 |
| Amortization of discounts on marketable investment securities | 33,908 | 92,625 |
| Accrued interest income | -6,460 | 1,285 |
| Prepaid and other current assets | 321,168 | -205,286 |
| Accounts payable | 418,458 | 171,298 |
| Accrued expenses | 63,888 | -235,461 |
| Cash used in operating activities | -2,985,723 | -3,855,491 |
| Purchases of marketable investment securities | 5,198,551 | 5,082,073 |
| Maturities of marketable investment securities | 5,900,000 | 8,700,000 |
| Net cash provided by investing activities | 701,449 | 3,617,927 |
| Net proceeds from sale of common stock through atm | 141,334 | 75,618 |
| Cash provided by financing activities | 141,334 | 75,618 |
| Net decrease in cash and cash equivalents | -2,142,940 | -161,946 |
| Cash and cash equivalents at beginning of period | 6,205,926 | - |
| Cash and cash equivalents at end of period | 3,901,040 | - |
Lipocine Inc. (LPCN)
Lipocine Inc. (LPCN)